Wide Ranks

CGTX

Cognition Therapeutics, Inc.

0.3979

Top Statistics
Market Cap 16 M Forward PE -0.4943 Revenue Growth 0.00 %
Current Ratio 3.07 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.1230 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 28 M Total Cash Per Share 0.7110 Total Debt 809000
Total Debt To Equity 3.52 Current Ratio 3.07 Book Value Per Share 0.7610
All Measures
Short Ratio 107.00 % Message Board Id finmb_39366358 Shares Short Prior Month 531392
Return On Equity -1.08 City Purchase Uuid a940fdf5-8e87-319f-94b8-efcb91259f97
Previous Close 0.4045 First Trade Date Epoch Utc 1 B Book Value 0.7610
Beta 1.33 Total Debt 809000 Volume 1 M
Price To Book 0.5229 Fifty Two Week Low 0.3400 Total Cash Per Share 0.7110
Shares Short Previous Month Date 1 B Target Median Price 5.00 Max Age 86400
Recommendation Mean 1.60 Sand P52 Week Change 0.3133 Target Mean Price 6.20
Net Income To Common -31082000 Short Percent Of Float 0.0294 Implied Shares Outstanding 41 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 5 M
Average Volume10days 5 M Total Cash 28 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0054 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 0.4045 Target Low Price 1.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.4750 Open 0.4050
Free Cashflow -29724750 State NY Dividend Yield 0.00 %
Return On Assets -0.9370 Time Zone Short Name EST Trailing Eps -0.9600
Day Low 0.3750 Address1 2500 Westchester Ave. Shares Outstanding 41 M
Price Hint 4 Target High Price 11.00 Website https://www.cogrx.com
52 Week Change -0.6414 Average Volume 1 M Forward Eps -0.7700
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 289.70 %
Is_sp_500 False Regular Market Day High 0.4085 Profit Margins 0.00 %
Debt To Equity 3.52 Fifty Two Week High 2.95 Day High 0.4085
Shares Short 815696 Regular Market Open 0.4050 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0203
Operating Cashflow -22858000 Currency USD Time Zone Full Name America/New_York
Market Cap 16 M Is_nasdaq_100 False Zip 10577
Quote Type EQUITY Industry Biotechnology Long Name Cognition Therapeutics, Inc.
Regular Market Day Low 0.3750 Held Percent Institutions 0.2453 Current Price 0.3979
Enterprise To Ebitda 0.1230 Financial Currency USD Current Ratio 3.07
Industry Disp Biotechnology Number Of Analyst Opinions 5 Country United States
Float Shares 33 M Two Hundred Day Average 1.36 Enterprise Value -7191977
Forward PE -0.4943 Regular Market Volume 1 M Ebitda -58609000
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.

Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.

The company was incorporated in 2007 and is headquartered in Purchase, New York.